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ABSTRACT
Objective: 21st century is dedicated to noncommunicable diseases; it may be diabetes, hypertension, obesity, or constellation of all known as metabolic 
syndrome. The main objective of this paper is to assess the prevalence of nonalcoholic fatty liver disease (NFLDS) in metabolic syndrome and its 
impact on the severity of metabolic syndrome in term of dyslipidemia, mean systolic pressure and body mass index (BMI).
Methods: A cross-sectional study was conducted on 100 patients selected randomly during the period of January 2017-March 2017 from the outdoor 
patient department of Kayachikitsa of All India Institute of Ayurveda. Patient included on the basis of a screening pro forma based on the diagnostic 
criteria of metabolic syndrome on the basis of Third Adult Treatment Panel of the National Cholesterol Education Program criteria and 50 controls 
were included in the study. Pro forma also included general information regarding previous illness, socioeconomical status, BMI, evaluation of vital 
parameters, and lipid and thyroid profile, along with other routine laboratory parameters. Ultrasonography report is taken as the evidence for the 
diagnosis of fatty liver disease.
Results: Frequency distributions and Chi-square statistics were used for categorical variables. Logistic regression analyses Students’ t-test, 
Chi-square test, linear regression, and multiple logistic regression models were used for statistical analysis. p<0.05 was considered significant. BMI, 
waist circumference, mean systolic pressure, diastolic blood pressure, fasting blood sugar, triglycerides, total cholesterol, low-density lipoprotein 
(LDL) cholesterol were significantly higher, and high-density lipoprotein cholesterol, was significantly low in the study group compared to the 
control group. In the metabolic syndrome group, 67 patients (67%) had fatty liver Grade I, 34 had Grade II fatty liver (34%), 6 patients were having 
hepatomegaly with coarse echotexture (6%) and 4 patients were having cholelithiasis. NFLDS was significantly associated with metabolic syndrome 
group (p<0.0001). There was a significant linear association between fatty infiltration in liver and BMI, total cholesterol, triglycerides, and LDL 
cholesterol in the metabolic syndrome group in the linear regression model. Multiple logistic regression analysis recognized the association between 
fatty liver disease and BMI with dyslipidemia (p<0.001) in the metabolic syndrome group.
Conclusion: It is concluded from this study that there is a significant association between NFLDS and metabolic syndrome, and it highlights the 
importance of evaluating liver profile in patients with metabolic syndrome.
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INTRODUCTION
Metabolic syndrome as per definition is a collection of medical 
conditions including high blood pressure, high fasting blood sugar level, 
increase waist circumference, abnormal cholesterol, or triglyceride 
level [1]. However, in this scenario, it seems that this definition should 
be redefine as in practice metabolic syndrome is found to invariably 
associated with nonalcoholic fatty liver disease (NFLDS). Thus, to quest 
the prevalence of NFLDS in metabolic syndrome following clinical study 
is planned. NFLDS is define as accumulation of fat (steatosis) in the liver 
which is not caused by alcohol consumption [2]. Incidence of NAFLD 
is increasing in both adult and children population [3,4]. The exact 
etiology of hepatic steatosis is not well understood, through its high 
occurrence in obesity (about 60% of obese and 90% of morbidly obese 
adults are having NAFLD) [5] signifies that dietary habits, sedentary 
life style and to some extent hereditary factors may have determinant 
role in pathogenesis. NAFLD is a broad term including simple steatosis, 
nonalcoholic steatohepatitis (NASH), fibrosis, and rarely, progression to 
cirrhosis [6]. Vivid cassette between insulin resistance, oxidative stress 
resulting in lipid peroxidation, proinflammatory cytokines, adipokines 
and mitochondrial dysfunction causes NAFLD [7]. Few previous studies 
reported the association of NAFLD and metabolic syndrome, but the 
data provided are mainly epidemiological and conceptual [8-10]. 
Hence, there is need of a research study to validate as well as assess 
the extent of association ship between metabolic syndrome and NAFLD.
METHODS
This cross-sectional study was conducted in Outpatient Department 
of Kayachikitsa, All India Institute of Ayurveda at New Delhi. 100 
known case of metabolic syndrome diagnosed on the basis of National 
Cholesterol Education Program-Adult Treatment Panel criteria 
(three out of five criteria should be positive, viz., blood pressure 
≥130/85 mmHg or taking antihypertensive medications, fasting blood 
glucose >100 mg/dl or taking antidiabetic medications, triglycerides 
>150 mg/dl, high-density lipoprotein cholesterol [HDL-C] <40 mg/dl in 
males, and <50 mg/dl in females, waist circumference >102 cm in men 
and 88 cm in women) were taken in the study group and 50 patients 
having no features of metabolic syndrome (0 out of 5 criteria) were 
taken in the control group. A written informed consent was obtained in 
the local language from every patient (or) his reliable caretaker before 
enrollment in the trial.
Evaluating scale
Screening pro forma
A pro forma is made for screening patients of metabolic syndrome 
and also assessing their demographic profile, history of previous 
illness and medication, anthropometric measurement including 
weight and height for calculating body mass index (BMI = weight in 
Kg/height in m2), waist circumference, measuring blood pressure 
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using standard sphygmomanometers. The value of variables is 
taken as per standard definition, say for example BMI <18.5 kg/m 
was categorize as underweight, BMI = 18.5-24.9 kg/m2 as normal, 
overweight if BMI = 25-29.9 kg/m2, and obesity if BMI> 30 kg/m2. 
Similarly, hypertension and hyperglycemia were categorized according 
to standard definition [11,12]. For measuring waist circumference, the 
distance between anterior superior iliac spines and the lower costal 
margin at the narrowest part of the waistline was calculated during 
expiration while putting patient in standing position.
Exclusion criteria
All patients having chronic renal disorder, congestive cardiac failure, 
altered thyroid profile, taking statins, or other medication that can 
alter the lipid profile, having past history of tuberculosis (ATT causes 
liver function derangement and may act as confounder) or hepatitis 
and history of any chronic illness such as polycystic ovarian disease 
and rheumatoid arthritis are also excluded keeping sick euthyroid 
syndrome in consideration.
Collection of data
All patients were undergone USG investigation for evaluating 
histopathology of the liver. Fasting blood samples were obtained for 
measuring FBS (venous blood samples taken after overnight fast 
of a minimum of 8 hrs); total cholesterol, low-density lipoprotein 
cholesterol (LDL-C), HDL-C, and triglyceride levels were measured.
Statistical analysis
Mean ± SD and percentage were used for assessing baseline 
characteristics of the study participants. For analyzing difference in 
baseline characteristic between the study and control groups, Student’s 
t-test was used. Linear regression model and Chi-square test were 
used to identify any significant association between the metabolic 
syndrome and NAFLD. Multiple logistic regression was used to analyze 
the associations between base characteristic of the study group (age, 
gender, mean blood pressure, fasting blood sugar total cholesterol, 
LDL-C, HDL-C, triglycerides, and waist circumference) and control group.
RESULT
Out of the 100 patients in the study group, 62 were females (62%) and 
38 were males (38%). In control group out of the 50 patients, 29 (58%) 
were females and 21 (42%) were males. The statistical analysis showing 
the difference between baseline characteristics of the two groups is 
given in Table 1. Both the groups were similar with respect to age and sex 
distribution to avoid maximum biasing. In the study group, 67 patients 
(67%) were having Grade I fatty liver, 34 (34%) were having Grade II 
fatty liver, six (6%) were having hepatomegaly with coarse echotexture 
(without any specification), and four (4%) had cholelithiasis. However, 
fasting blood sugar, mean systolic pressure, diastolic pressure, BMI, 
waist circumference, total cholesterol, LDL-C, and triglycerides were 
significantly higher in the study group as compared to the control group. 
HDL-C was found to be significantly lower in the study group.
The linear regression, assessing the correlation between the 
components of metabolic syndrome with the severity of NFLDS in terms 
of grading showed significant positive linear association with total 
cholesterol, triglycerides, LDL-C, FBS and systolic blood pressure and 
negative linear association with HDL. In the study group, 67 patients 
(67%) were having Grade I fatty liver, 34 patients (34%) were having 
Grade II fatty liver, six patients (6%) were having hepatomegaly with 
coarse echotexture (without any specification) and four patients (4%) 
had cholelithiasis. NAFLD had a significant association with metabolic 
syndrome as assessed by Chi-square test (p=0.001) (Table 2).
Logistic regression analysis showed significant association of NAFLD 
with LDL-C, triglyceride, and total cholesterol (p=0.000, CI-0.321-0.798) 
(Table 3).










Age 48.60±3.96 47.20±4.45 0.360
BMI 28.90±3.4 19.51±1.98 0.000
Waist circumference 88.90±4.2 85.34±4.23 0.001
FBS 130.63±28.21 87.02±8.76 0.001
SBP (mmHg) 140±20.2 119.82±9.98 0.001




LDL‑C (mg/dl) 116.56±24.45 86.50±18.59 0.001
HDL‑C (mg/dl) 42.34±5.64 48.87±8.92 0.005
Triglycerides 176.12±20.65 130.45±16.78 0.001
NAFLD Grade I 67.00±5.67 4.00±2.45 0.001
NAFLD Grade II 34.00±4.56 0.00 0.001
*BMI: Body mass index, FBS: Fasting blood sugar, LDL-C: Low-density 
lipoprotein cholesterol, HDL: High-density lipoprotein cholesterol, data are 
expressed in mean±standard deviation and p<0.005 is reported statistical 
significant, SBP: Systolic blood pressure, DBP: Diastolic blood pressure
Table 2: Correlation between components of metabolic 












*BMI: Body mass index, FBS: Fasting blood sugar, SBP: Systolic blood pressure, 
DBP: Diastolic blood pressure, LDL-C: Low-density lipoprotein cholesterol, 
HDL: High density lipoprotein cholesterol, β: Standardized linear regression 
coefficient
Table 3: Association between baseline characteristics and 








Age 1.958 1.156 3.314 0.012
BMI 1.310 0.670 2.562 0.429
FBS 1.328 0.860 2.050 0.200
SBP 1.714 1.128 2.603 0.011
DBP 1.707 1.081 2.697 0.021
TC 1.674 1.130 2.480 0.010
LDL-C 1.482 0.955 2.300 0.078
HDL-C 2.285 1.338 3.904 0.002
TG 1.666 1.125 2.468 0.010
WC 1.910 1.216 2.999 0.004
NAFLD 0.1194 0.041 0.346 0.000
*BMI: Body mass index, FBS: Fasting blood sugar, SBP: Systolic blood pressure, 
DBP: Diastolic blood pressure, LDL-C: Low-density lipoprotein cholesterol, 
HDL: High‑density lipoprotein cholesterol, β: Standardized linear regression 
coefficient
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DISCUSSION
This is a hospital-based cross-sectional study conducted in Outpatient 
Department of Kayachikitsa, All India Institute of Ayurveda, New Delhi. 
The hospital is situated at the heart of city and represent general 
population at large in general practice. The study group included 
100 patients with 62 females and 38 male. Control group included 
50 patients with 29 females and 21 males. Both the groups were similar 
in the distribution of age and gender. In the study group, BMI, waist 
circumference, fasting blood sugar, systolic and diastolic blood pressure, 
total cholesterol, LDL-C, and triglycerides were significantly higher than 
the control group, whereas HDL was significantly lower comparative to 
control group. NAFLD was found to be significantly associated with the 
metabolic syndrome, in control group only four patients were reported 
for having Grade I fatty liver with slightly higher level of LDL-C. Linear 
regression assessment showed a significant positive association of NAFLD 
with LDL-C, triglycerides and total cholesterol and negative association 
with HDL-C. The insignificant finding of NAFLD in control group suggests 
that metabolic syndrome is preceded by metabolic syndrome or it can be 
said that NAFLDS is probably the first clinical stage of disturb metabolic 
functions. Previous researches have also critically reviewed a possible 
relationship between NAFLD and metabolic syndrome, but clinical data 
required for establishing the strength of association is missing. Thus, 
this clinical study was planned with the aim to analyze the relation with 
the two clinical entities and their effect on treatment modality. There 
are many research studies that have shown the relation of NAFLD with 
the component of metabolic syndrome, viz., study conducted by Portillo 
Sanchez et al. showed that prevalence of NAFLD (50% and 56% of 
NAFLD patients, respectively) in overweight/obese patients with Type 2 
diabetes mellitus and having normal aminotransferases is much higher 
than previously reported [13]. They also reported that higher plasma 
A1c was associated with greater prevalence of NAFLD and accumulation 
of liver triglycerides (p=0.01). Patients with NAFLD had severe systemic 
(liver/muscle) and particularly adipose tissues insulin resistance 
(p<0.01). Bhatt and Smith had reported that NAFLD is highly prevent 
in Type 2 diabetes as well as Type 1. In Type 2 diabetes, its incidence is 
directly related to insulin resistance and obesity [14]. They suggested 
that weight reduction might prove helpful in reversing the pathology of 
NAFLD in Type 2 diabetes. A position paper published by the combined 
effort of Indian National Association for study of the liver, Endocrine 
Society of India, Indian College of Cardiology and Indian Society of 
Gastroenetrology gives the detail description about the association of 
NAFLD and metabolic syndrome in Indian population and recommended 
a multidisciplinary approach involving hepatologist, internists, 
cardiologist and also endocrinologists for the proper management of 
NAFLD [15]. Diehl in his article emphasizes the impact of fatty liver 
disease on hepatic complications such as fibrosis, cirrhosis, and even 
carcinoma [16]. He says that fatty liver disease should not be taken 
innocuous condition as previously assumed and give the evidence for 
its association with other morbid diseases such as metabolic syndrome 
and hypertension. The authors of the article carried out a survey study 
on selected subgroup of hypertensives who were having no risk factors 
for hepatic steatosis and reported that despite excluding all possible risk 
factors for fatty liver or hepatic steatosis 30% of the hypertensive were 
having fatty liver disease. He, further concluded that the prevalence 
of fatty liver disease in nonobese, nondiabetic hypertensive adults is 
almost two times to the historical prevalence of fatty liver in general 
population and almost three times to the age and sex matched group of 
parallel control. Zhang and Lu mentioned that at least 20-80% of NAFLD 
patients are having dyslipidemia (high level of triglycerides, LDL and low 
level of HDL) that increases the risk of cardiovascular complications in 
such patients [17]. They suggest that there exists a close relationship 
between Type 2 diabetes, obesity, metabolic syndrome and NAFLD. 
NASH significantly elevate the level of oxidized LDL-C. The characteristic 
feature of dyslipidemia in NAFLD is hypertriglyceridemia, low HDL-C 
and high LDL-C levels, which is atherogenic dyslipidemia. It is well-
known fact that dyslipidemia causes insulin resistance which in turn 
increases the free fatty acid (FFA) flux. The increased FFA level raises 
triglyceride and VLDL production and triggers oxidative stress and lipid 
peroxidation that deteriorates further the functioning of hepatocytes 
causing NAFLD and setting a vicious cycle [18]. Thus, it is evident from 
the above discussion that there is an established link between NAFLD 
and all the components of metabolic syndrome, i.e., hypertension, 
Type 2 diabetes, dyslipidemia and obesity and this clinical trial justified 
it by providing clinical data.
CONCLUSION
There exist a significant association between NFLDS and metabolic 
syndrome. This clinical trial showed that NAFLD relation with metabolic 
syndrome but further extensive studies is required to establish the 
cause and consequence relation between the two. The occurrence 
of fatty liver disease in control group suggest that it may be the first 
clinical sign signifying metabolic disturbance and necessitate the life 
style modulation and hypolipidemic drugs to prevent progression as 
metabolic syndrome.
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